Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Milestone Pharmaceuticals Inc. (MIST)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenue | | 1.0 | 1.5 | | | | | 15.0 |
| |
| Operating expenses | | | | | | | | |
| Research and development, net of tax credits | 8.6 | 10.3 | 9.8 | 10.7 | 8.8 | 10.9 | 9.7 | 9.4 |
| General and administrative | 4.4 | 3.9 | 4.0 | 3.9 | 3.6 | 3.8 | 3.0 | 3.0 |
| Commercial | 3.4 | 2.4 | 2.7 | 2.2 | 1.6 | 2.2 | 1.6 | 1.8 |
| Loss from operations | -16.4 | -15.5 | -15.0 | -16.8 | -14.0 | -16.9 | -14.3 | 0.7 |
| Interest income | 1.2 | 0.6 | 0.5 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 |
| Interest expense | -0.8 | | | | | | | |
| Net loss and comprehensive loss | -16.0 | -15.0 | -14.6 | -16.6 | -14.0 | -16.9 | -14.2 | 0.8 |
| Weighted average number of shares and pre-funded warrants outstanding, basic | 42.9 | 42.9 | 42.5 | 42.3 | 42.2 | | 42.2 | 41.7 |
| Weighted average number of shares and pre-funded warrants outstanding, diluted | 42.9 | 42.9 | 42.5 | 42.3 | 42.2 | | 42.2 | 44.5 |
| |
| Net loss per share, basic | ($0.37) | ($0.35) | ($0.34) | ($0.39) | ($0.33) | ($0.40) | ($0.34) | $0.02 |
| Net loss per share, diluted | ($0.37) | ($0.35) | ($0.34) | ($0.39) | ($0.33) | ($0.40) | ($0.34) | $0.02 |
|